PharmaMedic /
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
PharmaMedic
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us

MHRA announces new international recognition framework for MAs from 2024 9 Feb 2023

 

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the European Commission Decision Reliance Procedure (ECDRP) has been extended to 31 December 2023. After that a new international recognition framework will be instituted, from 1 January 2024.  

Companies receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) can continue to submit ECDRP Marketing Authorisation Applications (MAAs) to MHRA until the end of the year. From 2024, applications will be made through the MHRA’s new international recognition framework, which will take account of decisions already made by the European Medicines Agency and other regulators.  

 

Read more.

 

 

GeneralCategories

  • No categories

GeneralTags

#ABPI #ClinicalTrials #diagnostics #drugdevelopment #drugpricing #drugregulation #EC #EMA #EU #FDA #innovation #JPMorgan #lifesciences #marketaccess #MDR #medicalaffairs #medicaldevice #medicaldeviceregulation #medicaldevicesregulation #medtech #mentalhealth #mhra #NHS #NICE #outsourcing #pharmaregulation #pharmatrends #pre-eclampsia #R&D #raredisease #rarediseases #regulation #regulatory #UKgovernment #ukpharma #ukregulation #VPAS @PPharmamedic AI Biotech COVID-19 Healthcare Medical Affairs medicaldevices Pharma
PharmaMedic
  • Home
  • Join Us
  • Our Vision
  • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
Our Services
  • Start-Up
  • Product Launch
  • Product Development
Legal
  • Privacy Policy
  • Cookie Policy
Contact us
  • T:+44 (0) 208 168 1668
  • US Toll Free:+1 628 201 0911
  • [javascript protected email address]
  • The London Bioscience Innovation Centre (LBIC)
    2 Royal College Street
    London NW1 0NH

©2023 PharmaMedic. All Rights Reserved | Company Registration Number: 07364364 | VAT: 135986768

Powered by FL1 Digital